Type of Deal: 100% acquisition through equity subscription
Stake/Capacity: 100% shareholding acquired through subscription to 10,000 equity shares
Deal Value: USD 1,000,000 (approximately ₹8.3 crore at current exchange rates)
Funding Source: Cash consideration
Financial Impact: Not disclosed in the document. The company has subscribed to the initial share capital of USD 1,000,000 divided into 10,000 equity shares of USD 100 each.
Timeline: Transaction completed on September 11, 2026. No indicative time period for completion provided as the subsidiary was newly incorporated.
Strategic Rationale: The object of this subsidiary is to undertake Contract Research and Development services business as part of the acquisition of A1 Biochem Group previously disclosed on July 23, 2026. This represents expansion into contract research services in the US market.
Approval Status: No governmental or regulatory approvals required. The transaction is complete.
Related Party Aspects: A1 Biochem Labs (India) Private Limited is a step-down subsidiary of Aurobindo Pharma Limited (through Apitoria Pharma Private Limited, a wholly owned subsidiary) and therefore is a related party of the Company. Promoters and promoter group of the Company are not interested in the transaction. The transaction is executed at arms-length.
Entity Background: A1 Biochem USA Inc was incorporated on August 27, 2026 in USA. This is a newly incorporated company with no historical turnover data available. The company will carry out Contract Research and Development services business from USA.
